British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.
More...
Linear Mode
